Marathe, C.Rayner, C.Jones, K.Horowitz, M.2013-10-042013-10-042013Peptides, 2013; 44:75-860196-97811873-5169http://hdl.handle.net/2440/80360The gut derived peptides, glucagon-like peptides 1 and 2 (GLP-1 and GLP-2), are secreted following nutrient ingestion. GLP-1 and another gut peptide, glucose-dependent insulinotropic polypeptide (GIP) are collectively referred to as 'incretin' hormones, and play an important role in glucose homeostasis. Incretin secretion shares a complex interdependent relationship with both postprandial glycemia and the rate of gastric emptying. GLP-1 based therapies are now well established in the management of type 2 diabetes, while recent literature has suggested potential applications to treat obesity and protect against cardiovascular and neurological disease. The mechanism of action of GLP-2 is not well understood, but it shows promise as an intestinotropic agent.en© 2013 Elsevier Inc. All rights reserved.PancreasAnimalsHumansDiabetes Mellitus, Type 2Blood GlucoseReceptors, GlucagonGastric EmptyingPostprandial PeriodGlucagon-Like Peptide 1Glucagon-Like Peptide 2Clinical Trials as TopicIncretinsJournal article002013030710.1016/j.peptides.2013.01.0140003204796000112-s2.0-8487598545318951Rayner, C. [0000-0002-5527-256X]Jones, K. [0000-0002-1155-5816]Horowitz, M. [0000-0002-0942-0306]